Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.47 |
| ▸ | INSR | P06213 | 4/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 3/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578749 | 1.00 | SYK (0.50) | SYKKDRAURKBPTK2INSR | |
| SCHEMBL579032 | 0.92 | SYK (0.51) | SYKAURKBPTK2JAK2JAK1 | |
| SCHEMBL579033 | 0.92 | SYK (0.51) | SYKAURKBPTK2JAK2JAK1 | |
| SCHEMBL578928 | 0.91 | AURKA (0.53) | SYKAURKBPTK2JAK2JAK1 | |
| SCHEMBL578929 | 0.91 | AURKA (0.53) | SYKAURKBPTK2JAK2JAK1 | |
| SCHEMBL578714 | 0.90 | PTK2 (0.57) | SYKPTK2ALKNTRK1 | |
| SCHEMBL12174633 | 0.90 | PTK2 (0.57) | SYKPTK2ALKNTRK1 | |
| SCHEMBL578672 | 0.90 | PTK2 (0.57) | SYKPTK2ALKNTRK1 | |
| SCHEMBL578671 | 0.90 | PTK2 (0.57) | SYKPTK2ALKNTRK1 | |
| SCHEMBL13808220 | 0.88 | PTK2 (0.55) | SYKPTK2ALKNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4115907-B1 | COMBINATION DRUG OF KINASE INHIBITORS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-05-06 | — | — | EP | claimed |
| CN-114207437-B | Method for screening anticancer agent and combination drug of kinase inhibitor for treating pancreatic cancer | 国立大学法人北海道大学 | 2024-05-28 | — | — | CN | claimed |
| EP-4115907-A1 | METHOD FOR SCREENING ANTICANCER AGENT AND COMBINATION DRUG OF KINASE INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | National University Corporation Hokkaido University (JP) | 2023-01-11 | — | — | EP | claimed |
| US-20220387630-A1 | METHOD FOR SCREENING ANTICANCER AGENT AND COMBINATION DRUG OF KINASE INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-12-08 | — | — | US | claimed |
| CN-114207437-A | Method of screening anticancer agent and combination drug of kinase inhibitor for treating pancreatic cancer | 国立大学法人北海道大学 | 2022-03-18 | — | — | CN | claimed |
| EP-2027107-B1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | claimed |
| EP-4115907-B1 | COMBINATION DRUG OF KINASE INHIBITORS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-05-06 | — | — | EP | disclosed |
| CN-114207437-B | Method for screening anticancer agent and combination drug of kinase inhibitor for treating pancreatic cancer | 国立大学法人北海道大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-116334024-A | Aurora kinase B gene K85 and K87 mutation and application thereof | 北京大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116004567-A | Aurora kinase B gene K202 mutation and application thereof | 北京大学 | 2023-04-25 | — | — | CN | disclosed |
| EP-4115907-A1 | METHOD FOR SCREENING ANTICANCER AGENT AND COMBINATION DRUG OF KINASE INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | National University Corporation Hokkaido University (JP) | 2023-01-11 | — | — | EP | disclosed |
| US-20220387630-A1 | METHOD FOR SCREENING ANTICANCER AGENT AND COMBINATION DRUG OF KINASE INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-12-08 | — | — | US | disclosed |
| CN-114207437-A | Method of screening anticancer agent and combination drug of kinase inhibitor for treating pancreatic cancer | 国立大学法人北海道大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2027107-B1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2011134898-A1 | NEW COMBINATION THERAPY IN TREATMENT OF ONCOLOGICAL AND FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | WO | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| WO-2007132010-A1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | SYK 926/4885KDR 45/4885AURKB 1/4885 |
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | SYK 926/4885KDR 45/4885AURKB 1/4885 |
| US-20090163467-A1 | New compounds | CCNA1, MKI67, CCNT1 | SYK 3650/4885KDR 1793/4885AURKB 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.